Oculis (OCS) News Today $19.06 +0.50 (+2.69%) Closing price 10/7/2025 04:00 PM EasternExtended Trading$19.06 0.00 (-0.01%) As of 10/7/2025 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OCS Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Oculis price target raised to $30 from $28 at BofAOctober 7 at 4:29 PM | msn.comOculis Advances Privosegtor into Registrational Trials for Neuro-OphthalmologyOctober 7 at 11:27 AM | msn.comOculis price target raised to $36 from $33 at H.C. WainwrightOctober 7 at 11:27 AM | msn.comOculis (NASDAQ:OCS) Sees Unusually-High Trading Volume After Analyst UpgradeOctober 7 at 10:47 AM | marketbeat.comOculis (NASDAQ:OCS) Given New $36.00 Price Target at HC WainwrightOctober 7 at 8:15 AM | marketbeat.comOculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective TherapyOctober 6 at 4:07 AM | globenewswire.comOculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective TherapyOctober 6 at 4:07 AM | globenewswire.comOculis Holding AG (NASDAQ:OCS) Receives $35.75 Average Target Price from AnalystsOctober 6 at 3:08 AM | americanbankingnews.comOculis Holding AG (NASDAQ:OCS) Given Consensus Rating of "Moderate Buy" by AnalystsOctober 3, 2025 | marketbeat.comOculis Publishes Notification of Transactions by Person Discharging Managerial ResponsibilitiesSeptember 26, 2025 | globenewswire.comOculis Holding AG Announces Positive Phase 2 Results for Privosegtor in Acute Optic Neuritis at ECTRIMS 2025September 22, 2025 | quiverquant.comQOculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMSSeptember 22, 2025 | globenewswire.comOculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMSSeptember 22, 2025 | globenewswire.comOculis (NASDAQ:OCS) Cut to "Sell" at Wall Street ZenSeptember 21, 2025 | marketbeat.comOculis (NASDAQ:OCS) Upgraded by Wall Street Zen to "Hold" RatingSeptember 15, 2025 | marketbeat.comOculis Holding AG (NASDAQ:OCS) Short Interest UpdateSeptember 14, 2025 | marketbeat.comOculis Publishes Notifications of Transactions by Persons Discharging Managerial ResponsibilitiesSeptember 9, 2025 | globenewswire.com131,332 Shares in Oculis Holding AG $OCS Acquired by Alyeska Investment Group L.P.September 8, 2025 | marketbeat.comOculis (NASDAQ:OCS) Sees Large Volume Increase - What's Next?September 5, 2025 | marketbeat.comOculis Holding AG (NASDAQ:OCS) Sees Large Increase in Short InterestSeptember 5, 2025 | marketbeat.comOculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025September 4, 2025 | globenewswire.comOculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025September 4, 2025 | globenewswire.comOculis Holding AG to Present Phase 2 ACUITY Trial Results for Privosegtor and Expanded Phase 3 DIAMOND Data at EURETINA CongressSeptember 1, 2025 | quiverquant.comQOculis Holding AG to Present Phase 2 and Phase 3 Clinical Trial Results at EURETINA and Other Key Ophthalmology ConferencesSeptember 1, 2025 | quiverquant.comQOculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology ConferencesSeptember 1, 2025 | globenewswire.comOculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology ConferencesSeptember 1, 2025 | globenewswire.comOculis (NASDAQ:OCS) Coverage Initiated at Needham & Company LLCAugust 29, 2025 | marketbeat.comOculis Holding AG Management to Participate in September Investor ConferencesAugust 28, 2025 | quiverquant.comQOculis Holding AG to Participate in Notable Investor Conferences in September 2025August 28, 2025 | quiverquant.comQOculis to Participate in Upcoming September Investor ConferencesAugust 28, 2025 | globenewswire.comOculis to Participate in Upcoming September Investor ConferencesAugust 28, 2025 | globenewswire.comOculis initiated with a Buy at NeedhamAugust 27, 2025 | msn.comOculis Holding AG $OCS Shares Bought by Pivotal bioVenture Partners Investment Advisor LLCAugust 26, 2025 | marketbeat.comOculis Holding AG Appoints Mark Kupersmith, M.D. and Sebastian Wolf, M.D., Ph.D. as Chief Medical Advisors in Neuro-Ophthalmology and Ophthalmology RespectivelyAugust 25, 2025 | quiverquant.comQOculis Holding AG Appoints Mark Kupersmith, M.D. and Sebastian Wolf, M.D., Ph.D. as Chief Medical Advisors to Lead Advances in Neuro-Ophthalmology and OphthalmologyAugust 25, 2025 | quiverquant.comQOculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D.August 25, 2025 | globenewswire.comOculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D.August 25, 2025 | globenewswire.comOculis (NASDAQ:OCS) Releases Quarterly Earnings Results, Misses Estimates By $0.06 EPSAugust 24, 2025 | marketbeat.comOculis (NASDAQ:OCS) Price Target Raised to $33.00August 24, 2025 | marketbeat.comOculis reports Q2 EPS (49c), consensus (43c)August 23, 2025 | msn.comOculis Holding AG: Oculis Reports Q2 2025 Financial Results and Provides Company UpdateAugust 22, 2025 | finanznachrichten.deOculis Holding Reports Strong Financial Position in Mid-2025August 22, 2025 | msn.comOculis price target raised to $33 from $32 at H.C. WainwrightAugust 22, 2025 | msn.comOculis Holding AG Reports Q2 2025 Financial ProgressAugust 21, 2025 | tipranks.comOculis Reports Q2 2025 Financial Results and Provides Company UpdateAugust 21, 2025 | globenewswire.comOculis Reports Q2 2025 Financial Results and Provides Company UpdateAugust 21, 2025 | globenewswire.comUncovering Potential: Oculis Holding's Earnings PreviewAugust 20, 2025 | benzinga.comAberdeen Group plc Boosts Stake in Oculis Holding AG $OCSAugust 20, 2025 | marketbeat.comOculis (OCS) Expected to Announce Quarterly Earnings on TuesdayAugust 20, 2025 | marketbeat.com322,500 Shares in Oculis Holding AG (NASDAQ:OCS) Purchased by SR One Capital Management LPAugust 19, 2025 | marketbeat.com Get Oculis News Delivered to You Automatically Sign up to receive the latest news and ratings for OCS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OCS Media Mentions By Week OCS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OCS News Sentiment▼0.250.55▲Average Medical News Sentiment OCS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OCS Articles This Week▼104▲OCS Articles Average Week Get the Latest News and Ratings for OCS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Oculis and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies AMRX News Today QURE News Today XENE News Today VKTX News Today CGON News Today MOR News Today IMVT News Today APLS News Today RARE News Today HCM News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OCS) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredU.S. Government Blocked NVIDIA’s Buyout… Here’s WhyThe U.S. government doesn't normally block billion-dollar tech deals. But when NVIDIA tried to acquire this...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oculis Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Oculis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.